Actively Recruiting
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Led by All4Cure · Updated on 2024-05-03
450
Participants Needed
1
Research Sites
136 weeks
Total Duration
On this page
Sponsors
A
All4Cure
Lead Sponsor
J
Janssen Scientific Affairs, LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity. This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts classify patients based on whether care is delivered under an intention to adhere to an MRD-targeted clinical pathway, and if so, whether the implementation of that clinical pathway occurs through participation in the All4Cure platform vs. through written documentation. The three cohorts are labeled: Platform, Documentation, and Off-Pathway.
CONDITIONS
Official Title
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of multiple myeloma on or after the MRD-targeted clinical pathway launch in the Exigent network
- Diagnosis confirmed by medical record review with diagnostic code C90.00
- Age 18 years or older at diagnosis
- Continued care at a QCCA/Exigent Research practice for at least 90 days after diagnosis
- For Documentation Cohort: evidence of adherence or intention to adhere to the clinical pathway
- For Platform Cohort: patient registered in the All4Cure platform with signed HIPAA release
- For Platform Cohort: primary treating physician registered in the All4Cure platform
You will not qualify if you...
- Having another active cancer or treatment for another cancer within 3 years before multiple myeloma diagnosis, except basal or squamous cell skin cancer or in situ breast or cervix cancer
- Diagnosis of Immunoglobulin D (IgD) or Immunoglobulin E (IgE) multiple myeloma subtypes
- Transferring care outside the QCCA/Exigent Research network within 90 days after diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
All4Cure
Seattle, Washington, United States, 98126
Actively Recruiting
Research Team
J
Jennifer Wren, BS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here